Robert Andtbacka, MD | Authors

February 28, 2018

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses a study exploring the role of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with metastatic melanoma.

March 15, 2016

Instead of adjuvant treatment, Andtbacka suggests treating patients with melanoma in the neoadjuvant setting. The benefit of neoadjuvant treatment versus adjuvant treatment is that oncologists can see the effect on the tumor, as well as perform biopsies and be able to determine changes in the tumor to develop certain biomarkers.

July 16, 2013

Robert Andtbacka, MD, from the University of Utah School of Medicine and Huntsman Cancer Institute, discusses a trial analyzing talimogene laherparepvec (T-VEC) in melanoma.